CDMO Pemfailan SEC - Avid Bioservices, Inc.- Laporan Tahunan, Penyata Proksi, Prospektus

Statistik Asas

LEI	549300GRUS3ZMGP8MX22
CIK	704562

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Avid Bioservices, Inc.

SEC Filings (Chronological Order)

Halaman ini menyediakan senarai kronologi lengkap bagi Pemfailan SEC, tidak termasuk pemfailan pemilikan yang kami sediakan di tempat lain.

February 18, 2025	15-12G	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 15-12G 1 d912451d1512g.htm 15-12G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-32839 AVID BIOSERVICES, INC. (Exact na
February 5, 2025	EX-4.1	AVID BIOSERVICES, INC. U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION as Trustee FIRST SUPPLEMENTAL INDENTURE Dated as of February 5, 2025 7.00% Convertible Senior Notes due 2029 Exhibit 4.1 Execution Version AVID BIOSERVICES, INC. AND U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION as Trustee FIRST SUPPLEMENTAL INDENTURE Dated as of February 5, 2025 7.00% Convertible Senior Notes due 2029 FIRST SUPPLEMENTAL INDENTURE, dated as of February 5, 2025 (this “Supplemental Indenture”), among Avid Bioservices, Inc., a Delaware corporation (the “Company”), as issuer, and U.S. Bank T
February 5, 2025	S-8 POS	As filed with the Securities and Exchange Commission on February 5, 2025 As filed with the Securities and Exchange Commission on February 5, 2025 Registration No.
February 5, 2025	S-8 POS	As filed with the Securities and Exchange Commission on February 5, 2025 As filed with the Securities and Exchange Commission on February 5, 2025 Registration No.
February 5, 2025	EX-4.1	AVID BIOSERVICES, INC. U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION as Trustee FIRST SUPPLEMENTAL INDENTURE Dated as of February 5, 2025 7.00% Convertible Senior Notes due 2029 Exhibit 4.1 Execution Version AVID BIOSERVICES, INC. AND U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION as Trustee FIRST SUPPLEMENTAL INDENTURE Dated as of February 5, 2025 7.00% Convertible Senior Notes due 2029 FIRST SUPPLEMENTAL INDENTURE, dated as of February 5, 2025 (this “Supplemental Indenture”), among Avid Bioservices, Inc., a Delaware corporation (the “Company”), as issuer, and U.S. Bank T
February 5, 2025	S-8 POS	As filed with the Securities and Exchange Commission on February 5, 2025 As filed with the Securities and Exchange Commission on February 5, 2025 Registration No.
February 5, 2025	S-8 POS	As filed with the Securities and Exchange Commission on February 5, 2025 As filed with the Securities and Exchange Commission on February 5, 2025 Registration No.
February 5, 2025	EX-99.2	Avid Bioservices, Inc. Provides Notice of Fundamental Change and Make-Whole Fundamental Change to Holders of its Convertible Notes in Connection with Completed Merger Exhibit 99.2 Avid Bioservices, Inc. Provides Notice of Fundamental Change and Make-Whole Fundamental Change to Holders of its Convertible Notes in Connection with Completed Merger TUSTIN, Calif., February 5, 2025 — Avid Bioservices, Inc. (“Avid” or the “Company”), a dedicated biologics contract development and manufacturing organization (“CDMO”) working to improve patient lives by providing high q
February 5, 2025	EX-99.1	Avid Bioservices poised for significant growth with new partners GHO Capital and Ampersand Capital Partners Exhibit 99.1 Avid Bioservices poised for significant growth with new partners GHO Capital and Ampersand Capital Partners • Acquisition of biologics Contract Development and Manufacturing Organisation Avid Bioservices now completed • GHO and Ampersand’s deep experience in CDMO investing to support Avid’s next stage of rapid growth including expanded offerings, talent investment and greater geograph
February 5, 2025	S-8 POS	As filed with the Securities and Exchange Commission on February 5, 2025 As filed with the Securities and Exchange Commission on February 5, 2025 Registration No.
February 5, 2025	S-8 POS	As filed with the Securities and Exchange Commission on February 5, 2025 As filed with the Securities and Exchange Commission on February 5, 2025 Registration No.
February 5, 2025	EX-3.1	AMENDED AND RESTATED CERTIFICATE OF INCORPORATION AVID BIOSERVICES, INC. Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION of AVID BIOSERVICES, INC. 1. Name. The name of this corporation is Avid Bioservices, Inc. 2. Registered Office. The registered office of this corporation in the State of Delaware is: 251 Little Falls Drive, in the City of Wilmington, County of New Castle, Delaware, 19808. The name of its registered agent at such address is Corporation S
February 5, 2025	EX-99.1	Avid Bioservices poised for significant growth with new partners GHO Capital and Ampersand Capital Partners Exhibit 99.1 Avid Bioservices poised for significant growth with new partners GHO Capital and Ampersand Capital Partners • Acquisition of biologics Contract Development and Manufacturing Organisation Avid Bioservices now completed • GHO and Ampersand’s deep experience in CDMO investing to support Avid’s next stage of rapid growth including expanded offerings, talent investment and greater geograph
February 5, 2025	S-8 POS	As filed with the Securities and Exchange Commission on February 5, 2025 As filed with the Securities and Exchange Commission on February 5, 2025 Registration No.
February 5, 2025	8-K	Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 February 5, 2025 Date of Report (Date of earliest event reported) AVID BIOSERVICES, INC. (Exact name of registrant as specified in its charter) Commission File Number 001-32839 Delaware 95-3698422 (State or other jurisdiction of inco
February 5, 2025	EX-99.2	Avid Bioservices, Inc. Provides Notice of Fundamental Change and Make-Whole Fundamental Change to Holders of its Convertible Notes in Connection with Completed Merger Exhibit 99.2 Avid Bioservices, Inc. Provides Notice of Fundamental Change and Make-Whole Fundamental Change to Holders of its Convertible Notes in Connection with Completed Merger TUSTIN, Calif., February 5, 2025 — Avid Bioservices, Inc. (“Avid” or the “Company”), a dedicated biologics contract development and manufacturing organization (“CDMO”) working to improve patient lives by providing high q
February 5, 2025	S-8 POS	As filed with the Securities and Exchange Commission on February 5, 2025 As filed with the Securities and Exchange Commission on February 5, 2025 Registration No.
February 5, 2025	EX-3.1	AMENDED AND RESTATED CERTIFICATE OF INCORPORATION AVID BIOSERVICES, INC. Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION of AVID BIOSERVICES, INC. 1. Name. The name of this corporation is Avid Bioservices, Inc. 2. Registered Office. The registered office of this corporation in the State of Delaware is: 251 Little Falls Drive, in the City of Wilmington, County of New Castle, Delaware, 19808. The name of its registered agent at such address is Corporation S
February 5, 2025	8-K/A	Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 February 5, 2025 Date of Report (Date of earliest event reported) AVID BIOSERVICES, INC. (Exact name of registrant as specified in its charter) Commission File Number 001-32839 Delaware 95-3698422 (State or other jurisdiction of in
February 5, 2025	EX-3.2	BYLAWS AVID BIOSERVICES, INC. A DELAWARE CORPORATION Section 1. LAW, CERTIFICATE OF INCORPORATION AND BYLAWS Exhibit 3.2 BYLAWS OF AVID BIOSERVICES, INC. A DELAWARE CORPORATION Section 1. LAW, CERTIFICATE OF INCORPORATION AND BYLAWS 1.1. These bylaws are subject to the certificate of incorporation of the corporation (the “Certificate of Incorporation”). In these bylaws, references to law, the Certificate of Incorporation and bylaws mean the law, the provisions of the Certificate of Incorporation and thes
February 5, 2025	S-8 POS	As filed with the Securities and Exchange Commission on February 5, 2025 As filed with the Securities and Exchange Commission on February 5, 2025 Registration No.
February 5, 2025	S-8 POS	As filed with the Securities and Exchange Commission on February 5, 2025 As filed with the Securities and Exchange Commission on February 5, 2025 Registration No.
February 5, 2025	EX-99.25	EX-99.25 Cdmo-form25
February 5, 2025	EX-3.2	BYLAWS AVID BIOSERVICES, INC. A DELAWARE CORPORATION Section 1. LAW, CERTIFICATE OF INCORPORATION AND BYLAWS Exhibit 3.2 BYLAWS OF AVID BIOSERVICES, INC. A DELAWARE CORPORATION Section 1. LAW, CERTIFICATE OF INCORPORATION AND BYLAWS 1.1. These bylaws are subject to the certificate of incorporation of the corporation (the “Certificate of Incorporation”). In these bylaws, references to law, the Certificate of Incorporation and bylaws mean the law, the provisions of the Certificate of Incorporation and thes
January 30, 2025	EX-99.1	Avid Stockholders Approve Transaction with GHO and Ampersand Exhibit 99.1 Avid Stockholders Approve Transaction with GHO and Ampersand Tustin, CA, January 30, 2025 — Avid Bioservices, Inc. (NASDAQ: CDMO) (“Avid” or the “Company”), a dedicated biologics contract development and manufacturing organization (“CDMO”) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, to
January 30, 2025	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 January 30, 2025 Date of Report (Date of earliest event reported) AVID BIOSERVICES, INC. (Exact name of registrant as specified in its charter) Commission File Number 001-32839 Delaware 95-3698422 (State or other jurisdiction of inco
January 23, 2025	DEFA14A	UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of
January 22, 2025	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State
January 21, 2025	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State
January 8, 2025	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State
January 8, 2025	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State
December 30, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State
December 19, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State
December 18, 2024	DEFM14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 DEFM14A 1 ny20038150x5defm14a.htm DEFM14A TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for U
December 13, 2024	SC 13G	CDMO / Avid Bioservices, Inc. / GLAZER CAPITAL, LLC Passive Investment SC 13G 1 cdmo20241209.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 AVID BIOSERVICES, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 05368M106 (CUSIP Number) December 9, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designat
December 10, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2024 AVID BIOSERVICES, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2024 AVID BIOSERVICES, INC.
December 10, 2024	EX-99.1	Avid Bioservices Reports Financial Results for Second Quarter Ended October 31, 2024 Exhibit 99.1 Avid Bioservices Reports Financial Results for Second Quarter Ended October 31, 2024 TUSTIN, Calif., December 10, 2024 - Avid Bioservices, Inc. (NASDAQ: CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, t
December 10, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 31, 2024 ☐ TRANSITION REPORT PURSUANT T Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-32839
December 3, 2024	EX-FILING FEES	Calculation of Filing Fee Table SCHEDULE 14A (Form Type) Avid Bioservices, Inc. (Name of Registrant as Specified in its Charter) Table 1: Transaction Valuation Exhibit 107 Calculation of Filing Fee Table SCHEDULE 14A (Form Type) Avid Bioservices, Inc.
December 3, 2024	PREM14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by
November 14, 2024	EX-99.1	JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) EX-99.1 2 p24-3265exhibit99.htm JOINT FILING AGREEMENT PURSUANT TO RULE 13D-1(K) EXHIBIT 99.1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without
November 14, 2024	SC 13G/A	CDMO / Avid Bioservices, Inc. / Point72 Asset Management, L.P. Passive Investment SC 13G/A 1 p24-3265sc13ga.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Avid Bioservices, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 05368M106 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate bo
November 12, 2024	SC 13G/A	CDMO / Avid Bioservices, Inc. / INTEGRATED CORE STRATEGIES (US) LLC Passive Investment SC 13G/A 1 CDMOSC13GA2.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 2) AVID BIOSERVICES, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 05368M106 (CUSIP Number) NOVEMBER 7, 2024 (Date of event which requires filing of this statement) Check the appropri
November 7, 2024	EX-2.1	Agreement and Plan of Merger, dated as of November 6, 2024, by and among Avid Bioservices, Inc., Space Finco, Inc., and Space Mergerco, Inc. Exhibit 2.1 AGREEMENT AND PLAN OF MERGER by and among Space Finco, Inc., a Delaware corporation; Space Mergerco, Inc., a Delaware corporation; and Avid Bioservices, Inc., a Delaware corporation. Dated as of November 6, 2024 TABLE OF CONTENTS Page ARTICLE I. THE MERGER 2 Section 1.1 Merger 2 Section 1.2 Effect of the Merger 2 Section 1.3 Closing; Effective Time 2 Section 1.4 Certificate of Incorpor
November 7, 2024	EX-99.1	Avid Bioservices to be Acquired by GHO Capital Partners and Ampersand Capital Partners in $1.1 Billion Transaction Exhibit 99.1 Avid Bioservices to be Acquired by GHO Capital Partners and Ampersand Capital Partners in $1.1 Billion Transaction Tustin, CA, London, UK, and Boston, MA, November 6, 2024 — Avid Bioservices, Inc. (NASDAQ: CDMO) (“Avid” or the “Company”), a dedicated biologics contract development and manufacturing organization (“CDMO”) working to improve patient lives by providing high quality develo
November 7, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State
November 7, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 November 6, 2024 Date of Report (Date of earliest event reported) AVID BIOSERVICES, DEFA14A 1 ny20038150x2defa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 November 6, 2024 Date of Report (Date of earliest event reported) AVID BIOSERVICES, INC. (Exact name of registrant as specified in its charter) Commission File Number 001-32839 Delaware (Stat
November 7, 2024	EX-2.1	AGREEMENT AND PLAN OF MERGER by and among Space Finco, Inc., a Delaware corporation; Space Mergerco, Inc., a Delaware corporation; and Avid Bioservices, Inc., a Delaware corporation. Dated as of November 6, 2024 TABLE OF CONTENTS Exhibit 2.1 AGREEMENT AND PLAN OF MERGER by and among Space Finco, Inc., a Delaware corporation; Space Mergerco, Inc., a Delaware corporation; and Avid Bioservices, Inc., a Delaware corporation. Dated as of November 6, 2024 TABLE OF CONTENTS Page ARTICLE I. THE MERGER 2 Section 1.1 Merger 2 Section 1.2 Effect of the Merger 2 Section 1.3 Closing; Effective Time 2 Section 1.4 Certificate of Incorpor
November 7, 2024	EX-99.1	Avid Bioservices to be Acquired by GHO Capital Partners and Ampersand Capital Partners in $1.1 Billion Transaction Exhibit 99.1 Avid Bioservices to be Acquired by GHO Capital Partners and Ampersand Capital Partners in $1.1 Billion Transaction Tustin, CA, London, UK, and Boston, MA, November 6, 2024 — Avid Bioservices, Inc. (NASDAQ: CDMO) (“Avid” or the “Company”), a dedicated biologics contract development and manufacturing organization (“CDMO”) working to improve patient lives by providing high quality develo
November 7, 2024	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits false2024-11-04Avid Bioservices, Inc.0000704562NASDAQ00007045622024-11-042024-11-04 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 November 6, 2024 Date of Report (Date of earliest event reported) AVID BIOSERVICES, INC. (Exact name of registrant as specified in its charter) Commi
October 17, 2024	SC 13G/A	CDMO / Avid Bioservices, Inc. / STATE STREET CORP Passive Investment SC 13G/A 1 AvidBioservicesInc.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* AVID BIOSERVICES INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 05368M106 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursu
October 17, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 16, 2024 AVID BIOSERVICES, INC.
September 9, 2024	EX-99.1	Avid Bioservices Reports Financial Results for First Quarter Ended July 31, 2024 -- Recorded First Quarter Revenue of $40.2 Million -- -- Signed $66 Million in Net New Business, Resulting in Backlog of $219 Million -- -- Maintained FY2025 Revenue Gui Exhibit 99.1 Avid Bioservices Reports Financial Results for First Quarter Ended July 31, 2024 - Recorded First Quarter Revenue of $40.2 Million - - Signed $66 Million in Net New Business, Resulting in Backlog of $219 Million - - Maintained FY2025 Revenue Guidance of Between $160 Million and $168 Million - TUSTIN, Calif., September 9, 2024 - Avid Bioservices, Inc. (NASDAQ: CDMO), a dedicated biolog
September 9, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2024 ☐ TRANSITION REPORT PURSUANT TO S Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-32839 AVI
September 9, 2024	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 9, 2024 AVID BIOSERVICES, INC.
August 29, 2024	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 23, 2024 AVID BIOSERVICES, INC.
August 29, 2024	EX-10.1	Second Amendment to Avid Bioservices, Inc. Deferred Compensation Plan Exhibit 10.1 Second Amendment to the Avid Bioservices, Inc. Deferred Compensation Plan Effective as of July 7, 2023, Avid Bioservices, Inc., a Delaware corporation (the “Company”), established the Avid Bioservices, Inc. Deferred Compensation Plan (the “Plan”). The Plan was amended on one prior occasion. By adoption of this instrument, the Company now desires to amend the Plan to clarify that all d
August 28, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin
August 28, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin
July 2, 2024	EX-19.1	Securities Trading Policy EXHIBIT 19.1 SECURITIES TRADING POLICY (As Amended June 26, 2024) I. INTRODUCTION As a public company, Avid Bioservices, Inc. (“Avid” or the “Company”) is subject to various federal and state laws and regulations governing trading in its securities. It is the policy of Avid to comply fully, and to assist its employees in complying fully, with these laws and regulations. This Policy applies to all
July 2, 2024	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 2, 2024 AVID BIOSERVICES, INC.
July 2, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Tale of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended April 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-32839
July 2, 2024	EX-97.1	Avid Bioservices, Inc. Incentive-Based Compensation Recovery Policy EXHIBIT 97.1 Avid Bioservices, Inc. Incentive-BASED Compensation Recovery Policy Adopted by the Board of Directors on November 7, 2023 1. Policy Purpose. The purpose of this Avid Bioservices, Inc. (the “Company”) Incentive-Based Compensation Recovery Policy (this “Policy”) is to enable the Company to recover Erroneously Awarded Compensation in the event that the Company is required to prepare an A
July 2, 2024	EX-99.1	Avid Bioservices Reports Financial Results for Fourth Quarter and Fiscal Year Ended April 30, 2024 -- Recorded Fourth Quarter Revenue of $43.0 Million – Highest in Company History -- -- Signed $30 Million in Net New Business Resulting in Backlog of $ Exhibit 99.1 Avid Bioservices Reports Financial Results for Fourth Quarter and Fiscal Year Ended April 30, 2024 - Recorded Fourth Quarter Revenue of $43.0 Million – Highest in Company History - - Signed $30 Million in Net New Business Resulting in Backlog of $193 Million – - New Mammalian and Cell and Gene Therapy Facilities Fully Operational and in Service; Capital Expenditure Associated with Thr
April 26, 2024	EX-99	JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) EX-99 2 exhibit99.htm JOINT FILING AGREEMENT PURSUANT TO RULE 13D-1(K) EXHIBIT 99.1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the neces
April 26, 2024	SC 13G	CDMO / Avid Bioservices, Inc. / Point72 Asset Management, L.P. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Avid Bioservices, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 05368M106 (CUSIP Number) April 25, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to w
April 25, 2024	EX-99.1	Avid Bioservices Reports Financial Results for Third Quarter Ended January 31, 2024 -- Recorded Third Quarter Revenue of $33.8 Million -- -- Signed $41 Million in Net New Business Resulting in Record High Backlog of $206 Million -- -- Celebrated Comp Exhibit 99.1 Avid Bioservices Reports Financial Results for Third Quarter Ended January 31, 2024 - Recorded Third Quarter Revenue of $33.8 Million - - Signed $41 Million in Net New Business Resulting in Record High Backlog of $206 Million - - Celebrated Completion of Recent Expansion Program with Grand Opening of Cell and Gene Therapy Manufacturing Facility in January 2024 - - Completed Convertibl
April 25, 2024	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2024 AVID BIOSERVICES, INC.
April 24, 2024	10-Q/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2023 ☐ TRANSITION Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file n
April 24, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2024 ☐ TRANSITION REPORT PURSUANT T Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-32839
April 24, 2024	10-Q/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 31, 2023 ☐ TRANSITI Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission fil
April 24, 2024	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended April 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission fi
March 20, 2024	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 19, 2024 AVID BIOSERVICES, INC.
March 14, 2024	EX-10.1	Amendment No. 2 to Credit Agreement, dated as of March 12, 2024, by and among Avid Bioservices, Inc., as the Borrower, the Lenders party thereto, and Bank of America, N.A., as Administrative Agent Exhibit 10.1 AMENDMENT NO. 2 TO CREDIT AGREEMENT THIS AMENDMENT NO. 2 TO CREDIT AGREEMENT, dated as of March 12, 2024 (this “Amendment”), is by and among AVID BIOSERVICES, INC. (the “Borrower”), the Lenders party hereto, and BANK OF AMERICA, N.A., as administrative agent (in such capacity, the “Administrative Agent”). Capitalized terms used herein and not otherwise defined herein shall have the me
March 14, 2024	EX-4.1	Indenture, dated as of March 12, 2024, by and between Avid Bioservices, Inc. and U.S. Bank Trust Company, National Association, as trustee Exhibit 4.1 AVID BIOSERVICES, INC., as Issuer AND U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of March 12, 2024 7.00% Convertible Senior Notes due 2029 TABLE OF CONTENTS Page Article 1 Definitions Section 1.01. Definitions 1 Section 1.02. References to Interest 9 Article 2 Issue, Description, Execution, Registration and Conversion of Notes Section 2.01. Designation
March 14, 2024	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2024 AVID BIOSERVICES, INC.
March 12, 2024	NT 10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING Commission File Number 001-32839 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
March 12, 2024	8-K	Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2024 AVID BIOSERVICES, INC.
March 7, 2024	EX-99.1	Avid Bioservices Announces Certain Preliminary Financial Results for Third Quarter Ended January 31, 2024 Exhibit 99.1 Avid Bioservices Announces Certain Preliminary Financial Results for Third Quarter Ended January 31, 2024 TUSTIN, Calif., March 6, 2024 - Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceuti
March 7, 2024	8-K	Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2024 AVID BIOSERVICES, INC.
March 7, 2024	EX-99.1	Avid Bioservices Announces Proposed Private Placement of Convertible Notes Exhibit 99.2 Avid Bioservices Announces Proposed Private Placement of Convertible Notes TUSTIN, Calif., March 6, 2024 - Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO), announced today that it intends to offer, subject to market conditions and other factors, $160 million aggregate principal amount of Convertible Senior Notes du
March 7, 2024	EX-99.1	Avid Bioservices Announces Pricing of Private Placement of Convertible Notes Exhibit 99.3 Avid Bioservices Announces Pricing of Private Placement of Convertible Notes TUSTIN, Calif., March 6, 2024 - Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO), announced today the pricing of $160 million aggregate principal amount of 7.00% Convertible Senior Notes due 2029 (the “2029 Notes”). In connection with the o
March 6, 2024	8-K	Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 29, 2024 AVID BIOSERVICES, INC.
February 13, 2024	SC 13G/A	CDMO / Avid Bioservices, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0374-avidbioservicesinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: Avid Bioservices Inc Title of Class of Securities: Common Stock CUSIP Number: 05368M106 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to desig
January 8, 2024	SC 13G/A	CDMO / Avid Bioservices, Inc. / INTEGRATED CORE STRATEGIES (US) LLC Passive Investment SC 13G/A 1 CDMOSC13GA12024.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 1) AVID BIOSERVICES, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 05368M106 (CUSIP Number) DECEMBER 31, 2023 (Date of event which requires filing of this statement) Check the app
December 19, 2023	SC 13G	CDMO / Avid Bioservices, Inc. / INTEGRATED CORE STRATEGIES (US) LLC Passive Investment SC 13G 1 CDMOSC13GDec2023.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 AVID BIOSERVICES, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 05368M106 (CUSIP Number) DECEMBER 12, 2023 (Date of event which requires filing of this statement) Check the appropriate box to des
December 7, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 31, 2023 ☐ TRANSITION REPORT PURSUANT T Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-32839
December 7, 2023	EX-99.1	Avid Bioservices Reports Financial Results for Second Quarter Ended October 31, 2023 -- Recorded Second Quarter Revenue of $25.4 Million -- -- Signed $35 Million in Net New Business Orders Resulting in a Backlog of $199 Million -- -- Entered into Par Exhibit 99.1 Avid Bioservices Reports Financial Results for Second Quarter Ended October 31, 2023 - Recorded Second Quarter Revenue of $25.4 Million - - Signed $35 Million in Net New Business Orders Resulting in a Backlog of $199 Million - - Entered into Partnership with California Institute of Regenerative Medicine (CIRM) to Advance Manufacturing of Adeno-Associated Adenovirus, as well as Other C
December 7, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 7, 2023 AVID BIOSERVICES, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 7, 2023 AVID BIOSERVICES, INC.
December 6, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2023 AVID BIOSERVICES, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2023 AVID BIOSERVICES, INC.
December 6, 2023	EX-99.1	Corporate Presentation December 2023 2 CONFIDENTIAL Safe Harbor Statement Some of the statements in this presentation contain forward - looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Exhibit 99.1 Corporate Presentation December 2023 2 CONFIDENTIAL Safe Harbor Statement Some of the statements in this presentation contain forward - looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. These forward - looking statements reflect
November 17, 2023	8-K/A	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A (Amendment No.
November 14, 2023	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2023 AVID BIOSERVICES, INC.
November 14, 2023	EX-10.1	First Amendment to Avid Bioservices, Inc. Deferred Compensation Plan Exhibit 10.1 First Amendment to the Avid Bioservices, Inc. Deferred Compensation Plan Effective as of July 7, 2023, Avid Bioservices, Inc., a Delaware corporation (the “Company”), established the Avid Bioservices, Inc. Deferred Compensation Plan (the “Plan”). By adoption of this instrument, the Company now desires to amend the Plan to make the clarifying and administrative changes set forth below.
November 2, 2023	EX-10.1	Amendment No. 1 to Credit Agreement, dated as of October 27, 2023, among Avid Bioservices, Inc., as the Borrower, the Lenders party hereto, and Bank of America, N.A., as Administrative Agent. Exhibit 10.1 AMENDMENT NO. 1 TO CREDIT AGREEMENT THIS AMENDMENT NO. 1 TO CREDIT AGREEMENT, dated as of October 27, 2023 (this “Amendment”), is by and among AVID BIOSERVICES, INC. (the “Borrower”), the Lenders party hereto, and BANK OF AMERICA, N.A., as administrative agent (in such capacity, the “Administrative Agent”). Capitalized terms used herein and not otherwise defined herein shall have the
November 2, 2023	8-K	Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 27, 2023 AVID BIOSERVICES, INC.
October 25, 2023	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 23, 2023 AVID BIOSERVICES, INC.
September 7, 2023	EX-99.1	Avid Bioservices Reports Financial Results for First Quarter Ended July 31, 2023 -- Recorded First Quarter Revenue of $37.7 Million -- -- Signed $36 Million in Net New Business Orders Resulting in a Backlog of $189 Million -- -- Cell and Gene Therapy Exhibit 99.1 Contacts: Stephanie Diaz (Investors) Tim Brons (Media) Vida Strategic Partners Vida Strategic Partners 415-675-7401 415-675-7402 [email protected] [email protected] Avid Bioservices Reports Financial Results for First Quarter Ended July 31, 2023 - Recorded First Quarter Revenue of $37.7 Million - - Signed $36 Million in Net New Business Orders Resulting in a Backlog of $189 Million - -
September 7, 2023	EX-FILING FEES	Filing Fee Table Exhibit 107.1 Calculation of Filing Fee Table Form S-8 (Form Type) Avid Bioservices, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Debt(1) Deferred Compensation Obl
September 7, 2023	S-8	As filed with the Securities and Exchange Commission on September 7, 2023 As filed with the Securities and Exchange Commission on September 7, 2023 Registration No.
September 7, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2023 ☐ TRANSITION REPORT PURSUANT TO S Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-32839 AVI
September 7, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 7, 2023 AVID BIOSERVICES, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 7, 2023 AVID BIOSERVICES, INC.
August 28, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin
August 28, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin
July 13, 2023	EX-10.2	Form of Notice of Grant of Performance Stock Unit Award Exhibit 10.2 FORM OF NOTICE OF GRANT OF PERFORMANCE STOCK UNIT AWARD AVID BIOSERVICES, INC. 2018 OMNIBUS INCENTIVE PLAN FOR GOOD AND VALUABLE CONSIDERATION, Avid Bioservices, Inc. (the “Company”) hereby grants this Performance Stock Unit Award (the “Award”) of the number of Performance Stock Units set forth in this Notice of Grant of Performance Stock Unit Award (the “Notice”) to the Grantee desig
July 13, 2023	EX-10.1	Avid Bioservices, Inc. Deferred Compensation Plan Exhibit 10.1 Avid Bioservices, Inc. Deferred Compensation Plan PREAMBLE By the adoption of this document, Avid Bioservices, Inc., a Delaware corporation (the “Company”), hereby establishes the Avid Bioservices, Inc. Deferred Compensation Plan (the “Plan”). The purpose of the Plan is to allow eligible employees and directors of the Company to meet their retirement savings goals. To achieve this obj
July 13, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 7, 2023 AVID BIOSERVICES, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 7, 2023 AVID BIOSERVICES, INC.
June 23, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 19, 2023 AVID BIOSERVICES, INC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 19, 2023 AVID BIOSERVICES, INC.
June 23, 2023	EX-3.2	Amended and Restated Bylaws, as adopted on June 19, 2023 Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF AVID BIOSERVICES, INC., a Delaware corporation June 19, 2023 Table of Contents Page Article I OFFICES 1 Section 1. Registered Office 1 Section 2. Other Offices 1 Section 3. Books 1 Article II MEETINGS OF STOCKHOLDERS 1 Section 1. Place of Meetings 1 Section 2. Annual Meetings 1 Section 3. Special Meetings 4 Section 4. Notice; Waiver of Notice 5 Section 5.
June 21, 2023	EX-4.4	Description of Registrant’s Securities EXHIBIT 4.4 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following summary of the rights of our common stock, $0.001 par value per share (“Common Stock”), and preferred stock, $0.001 par value per share (“Preferred Stock”), does not purport to be complete. This summary is subject to and qualified by the provisions of our re
June 21, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2023 AVID BIOSERVICES, INC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2023 AVID BIOSERVICES, INC.
June 21, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended April 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-32839
June 21, 2023	EX-99.1	Avid Bioservices Reports Financial Results for Fourth Quarter and Fiscal Year Ended April 30, 2023 -- Fourth Quarter and Full Year Revenue of $39.8 Million and $149.3 Million, Respectively, Both Represent a Record-High Achievement -- -- Signed $55 Mi Exhibit 99.1 Contacts: Stephanie Diaz (Investors) Tim Brons (Media) Vida Strategic Partners Vida Strategic Partners 415-675-7401 415-675-7402 [email protected] [email protected] Avid Bioservices Reports Financial Results for Fourth Quarter and Fiscal Year Ended April 30, 2023 - Fourth Quarter and Full Year Revenue of $39.8 Million and $149.3 Million, Respectively, Both Represent a Record-High Achie
March 15, 2023	EX-10.1	Credit Agreement, dated as of March 14, 2023, among Avid Bioservices, Inc., as the Borrower, the Guarantors Party Hereto, the Lenders Party Hereto, and Bank of Americal, N.A., as Administrative Agent and L/C Issuer Exhibit 10.1 CREDIT AGREEMENT Dated as of March 14, 2023 among AVID BIOSERVICES, INC., as the Borrower, CERTAIN SUBSIDIARIES OF THE BORROWER PARTY HERETO, as the Guarantors, BANK OF AMERICA, N.A., as Administrative Agent and L/C Issuer, and THE LENDERS PARTY HERETO BOFA SECURITIES, INC., as Sole Lead Arranger and Sole Bookrunner TABLE OF CONTENTS Page Article I DEFINITIONS AND ACCOUNTING TERMS 1 1
March 15, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2023 AVID BIOSERVICES, IN UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2023 AVID BIOSERVICES, INC.
March 13, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2023 AVID BIOSERVICES, IN UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2023 AVID BIOSERVICES, INC.
March 13, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2023 ☐ TRANSITION REPORT PURSUANT T Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-32839
March 13, 2023	EX-99.1	Avid Bioservices Reports Financial Results for Third Quarter Ended January 31, 2023, and Recent Developments -- Recorded Third Quarter Revenue of $38.0 Million, a 21% Increase Compared to Prior Year Quarter -- -- Signed $67 Million in Net New Busines Exhibit 99.1 Contacts: Stephanie Diaz (Investors) Tim Brons (Media) Vida Strategic Partners Vida Strategic Partners 415-675-7401 415-675-7402 [email protected] [email protected] Avid Bioservices Reports Financial Results for Third Quarter Ended January 31, 2023, and Recent Developments - Recorded Third Quarter Revenue of $38.0 Million, a 21% Increase Compared to Prior Year Quarter - - Signed $67 Mi
March 10, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 AVID BIOSERVICES, IN UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 AVID BIOSERVICES, INC.
February 9, 2023	SC 13G/A	CDMO / Avid Bioservices Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0350-avidbioservicesinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Avid Bioservices Inc. Title of Class of Securities: Common Stock CUSIP Number: 05368M106 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to desi
December 9, 2022	EX-10.1	Executive Severance Plan adopted December 5, 2022 Exhibit 10.1 AVID BIOSERVICES, INC. EXECUTIVE SEVERANCE PLAN 1. Purpose. The purpose of this Avid Bioservices, Inc. Executive Severance Plan (the ?Plan?) is to encourage employees of Avid Bioservices, Inc. (the ?Company?) to remain in the employ of the Company and its Affiliates by providing severance protections to such employees in the event that their employment is terminated under the circumst
December 9, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 5, 2022 AVID BIOSERVICES, INC.
December 6, 2022	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2022 AVID BIOSERVICES, INC.
December 6, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 31, 2022 ☐ TRANSITION REPORT PURSUANT T Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-32839
December 6, 2022	EX-99.1	Avid Bioservices Reports Financial Results for Second Quarter Ended October 31, 2022 and Recent Developments -- Recorded Second Quarter Revenue of $34.8 Million -- -- Signed $26 Million in Net New Business Orders Resulting in a Backlog of $147 Millio Exhibit 99.1 Contacts: Stephanie Diaz (Investors) Tim Brons (Media) Vida Strategic Partners Vida Strategic Partners 415-675-7401 415-675-7402 [email protected] [email protected] Avid Bioservices Reports Financial Results for Second Quarter Ended October 31, 2022 and Recent Developments - Recorded Second Quarter Revenue of $34.8 Million - - Signed $26 Million in Net New Business Orders Resulting in
October 21, 2022	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 18, 2022 AVID BIOSERVICES, INC.
October 21, 2022	EX-3.1	Certificate of Amendment to Restated Certificate of Incorporation, as filed with the Delaware Secretary of State on October 19, 2022 Exhibit 3.1 CERTIFICATE OF AMENDMENT OF RESTATED CERTIFICATE OF INCORPORATION OF AVID BIOSERVICES, INC. AVID BIOSERVICES, INC., a corporation duly organized and existing under the General Corporation Law of the State of Delaware (the ?Corporation?), does hereby certify that: 1. The Restated Certificate of Incorporation of the Corporation, as amended to date, is hereby further amended by striking o
September 6, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2022 ☐ TRANSITION REPORT PURSUANT TO S Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-32839 AVI
September 6, 2022	8-K	Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 6, 2022 AVID BIOSERVICES, INC.
September 6, 2022	EX-99.1	Avid Bioservices Reports Financial Results for First Quarter Ended July 31, 2022 and Recent Developments -- Recorded First Quarter Revenue of $36.7 Million -- -- Signed $41 Million in Net New Business Orders and Ended the Quarter with a Record High B Exhibit 99.1 Contacts: Stephanie Diaz (Investors) Tim Brons (Media) Vida Strategic Partners Vida Strategic Partners 415-675-7401 415-675-7402 [email protected] [email protected] Avid Bioservices Reports Financial Results for First Quarter Ended July 31, 2022 and Recent Developments - Recorded First Quarter Revenue of $36.7 Million - - Signed $41 Million in Net New Business Orders and Ended the Quar
August 29, 2022	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin
August 29, 2022	DEFA14A	NOTICE AND ACCESS DEFA14A 1 aviddefa14a.htm NOTICE AND ACCESS
August 19, 2022	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin
July 14, 2022	EX-10.1	Form of Notice of Performance Stock Unit Award under 2018 Omnibus Incentive Plan Exhibit 10.1 FORM OF NOTICE OF GRANT OF PERFORMANCE STOCK UNIT AWARD AVID BIOSERVICES, INC. 2018 OMNIBUS INCENTIVE PLAN FOR GOOD AND VALUABLE CONSIDERATION, Avid Bioservices, Inc. (the ?Company?) hereby grants this Performance Stock Unit Award (the ?Award?) of the number of Performance Stock Units set forth in this Notice of Grant of Performance Stock Unit Award (the ?Notice?) to the Grantee desig
July 14, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 9, 2022 AVID BIOSERVICES, INC.
June 29, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended April 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-32839
June 29, 2022	S-8	As filed with the Securities and Exchange Commission on June 29, 2022 As filed with the Securities and Exchange Commission on June 29, 2022 Registration No.
June 29, 2022	EX-4.4	Description of Registrant’s Securities EXHIBIT 4.4 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following summary of the rights of our common stock, $0.001 par value per share (?Common Stock?), and preferred stock, $0.001 par value per share (?Preferred Stock?), does not purport to be complete. This summary is subject to and qualified by the provisions of our ce
June 29, 2022	EX-FILING FEES	Filing Fee Table EXHIBIT 107 Calculation of Filing Fee Table Form S-8 Avid Bioservices, Inc. Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, $0.001 par value per share Other 3,400,000 (2) $14.56 (3) $49,504,000(3) $0.0000927 $4,589.02 Total Offering Amoun
June 29, 2022	EX-99.1	Avid Bioservices Reports Financial Results for Fourth Quarter and Full Fiscal Year Ended April 30, 2022 and Recent Developments -- Recorded Fourth Quarter and Full Fiscal Year Revenue of $31 Million and $120 Million, Respectively -- -- Signed $44 Mil Exhibit 99.1 Contacts: Stephanie Diaz (Investors) Tim Brons (Media) Vida Strategic Partners Vida Strategic Partners 415-675-7401 415-675-7402 [email protected] [email protected] Avid Bioservices Reports Financial Results for Fourth Quarter and Full Fiscal Year Ended April 30, 2022 and Recent Developments - Recorded Fourth Quarter and Full Fiscal Year Revenue of $31 Million and $120 Million, Respect
June 29, 2022	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29, 2022 AVID BIOSERVICES, INC.
March 8, 2022	EX-99.1	Avid Bioservices Reports Financial Results for Third Quarter Ended January 31, 2022 and Recent Developments -- Recorded Third Quarter Revenue of $31.5 Million -- -- Myford South and Viral Vector Facilities Construction Continues On Schedule -- -- Sig Exhibit 99.1 Contacts: Stephanie Diaz (Investors) Tim Brons (Media) Vida Strategic Partners Vida Strategic Partners 415-675-7401 415-675-7402 [email protected] [email protected] Avid Bioservices Reports Financial Results for Third Quarter Ended January 31, 2022 and Recent Developments - Recorded Third Quarter Revenue of $31.5 Million - - Myford South and Viral Vector Facilities Construction Continu
March 8, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2022 ☐ TRANSITION REPORT PURSUANT T Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-32839
March 8, 2022	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2022 AVID BIOSERVICES, INC.
February 9, 2022	SC 13G	CDMO / Avid Bioservices Inc / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Avid Bioservices Inc. Title of Class of Securities: Common Stock CUSIP Number: 05368M106 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(b) ☐ R
January 10, 2022	EX-99.1	Avid Bioservices Announces Official Opening of Second Downstream Processing Suite Within Myford North Facility Milestone Marks Completion of First Phase of Two-Part Myford Facility Expansion; First Customer Project to Begin in New Downstream Processi Exhibit 99.1 Contacts: Stephanie Diaz (Investors) Tim Brons (Media) Vida Strategic Partners Vida Strategic Partners 415-675-7401 415-675-7402 [email protected] [email protected] Avid Bioservices Announces Official Opening of Second Downstream Processing Suite Within Myford North Facility Milestone Marks Completion of First Phase of Two-Part Myford Facility Expansion; First Customer Project to Begin
January 10, 2022	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2022 AVID BIOSERVICES, INC.
December 7, 2021	EX-10.1	First Amendment to the Avid Bioservices, Inc. 2018 Omnibus Incentive Plan. Exhibit 10.1 FIRST AMENDMENT TO THE AVID BIOSERVICES, INC. 2018 OMNIBUS INCENTIVE PLAN Avid Bioservices, Inc., a Delaware corporation (the ?Company?), previously established the Avid Bioservices, Inc. 2018 Omnibus Incentive Plan (the ?Plan?). The Plan was adopted by the Board of Directors on August 6, 2018 and approved by the Company?s stockholders at the 2018 Annual Meeting. By adoption of this i
December 7, 2021	EX-99.1	Press Release issued December 7, 2021. Exhibit 99.1 Contacts: Stephanie Diaz (Investors) Tim Brons (Media) Vida Strategic Partners Vida Strategic Partners 415-675-7401 415-675-7402 [email protected] [email protected] Avid Bioservices Reports Financial Results for Second Quarter Ended October 31, 2021 and Recent Developments ? Recorded Second Quarter Revenue of $26.1 Million ? ? Initiated Strategic Expansion into Viral Vector Development
December 7, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-32839
December 7, 2021	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 7, 2021 AVID BIOSERVICES, INC.
November 4, 2021	EX-99.1	Avid Bioservices Appoints Elie G. Hanania, Ph.D., as Vice President, Process Development, Viral Vector Technologies Seasoned Life Science Industry Executive with More Than 30 Years of Experience in Cell and Gene Therapy, Including Senior Level Viral EX-99.1 2 avidex9901.htm PRESS RELEASE Exhibit 99.1 Contacts: Stephanie Diaz (Investors) Tim Brons (Media) Vida Strategic Partners Vida Strategic Partners 415-675-7401 415-675-7402 [email protected] [email protected] Avid Bioservices Appoints Elie G. Hanania, Ph.D., as Vice President, Process Development, Viral Vector Technologies Seasoned Life Science Industry Executive with More Than 30 Years of
November 4, 2021	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2021 AVID BIOSERVICES, INC.
October 28, 2021	SC 13G/A	CDMO / Avid Bioservices Inc / Tappan Street Partners LLC - AMENDMENT TO SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934* (Amendment No. 7) Avid Bioservices, Inc. (Name of Issuer) Common Stock ($0.001 par value) (Title of Class of Securities) 05368M106 (CUSIP Number) October 26, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu
October 26, 2021	EX-99.1	AVID BIOSERVICES to join S&P Smallcap 600 Index Exhibit 99.1 Contacts: Stephanie Diaz (Investors) Tim Brons (Media) Vida Strategic Partners Vida Strategic Partners 415-675-7401 415-675-7402 [email protected] [email protected] AVID BIOSERVICES to join S&P Smallcap 600 Index TUSTIN, CA, October 26, 2021 - Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patien
October 26, 2021	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 26, 2021 AVID BIOSERVICES, INC.
October 22, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 21, 2021 AVID BIOSERVICES, INC.
October 14, 2021	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 14, 2021 AVID BIOSERVICES, INC.
October 14, 2021	EX-99.1	AVID BIOSERVICES announces expansion into viral vector development and manufacturing services for cell and gene therapy Leverages Established Track Record of Excellence in Biologics CGMP Manufacturing to Address the Rapidly Growing Cell and Gene Ther Exhibit 99.1 Contacts: Stephanie Diaz (Investors) Tim Brons (Media) Vida Strategic Partners Vida Strategic Partners 415-675-7401 415-675-7402 [email protected] [email protected] AVID BIOSERVICES announces expansion into viral vector development and manufacturing services for cell and gene therapy Leverages Established Track Record of Excellence in Biologics CGMP Manufacturing to Address the Rapidly
October 8, 2021	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 7, 2021 AVID BIOSERVICES, INC.
October 8, 2021	EX-99.1	Avid Bioservices Appoints Matthew Kwietniak as Chief Commercial Officer Accomplished Senior Executive with Nearly 30 Years of Sales Experience Spanning CDMO Offerings, Clinical Development Services and Scientific Products Exhibit 99.1 Contacts: Stephanie Diaz (Investors) Tim Brons (Media) Vida Strategic Partners Vida Strategic Partners 415-675-7401 415-675-7402 [email protected] [email protected] Avid Bioservices Appoints Matthew Kwietniak as Chief Commercial Officer Accomplished Senior Executive with Nearly 30 Years of Sales Experience Spanning CDMO Offerings, Clinical Development Services and Scientific Products T
September 8, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2021 ☐ TRANSITION REPORT PURSUANT TO S Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-32839 AVI
September 8, 2021	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 8, 2021 AVID BIOSERVICES, INC.
September 8, 2021	EX-99.1	Avid Bioservices Reports Financial Results for First Quarter Ended July 31, 2021 and Recent Developments -- Recorded First Quarter Revenue of $30.8 Million -- -- Achieved Fifth Consecutive Quarter of Operational Profitability -- -- Signed $23 Million Exhibit 99.1 Contacts: Stephanie Diaz (Investors) Tim Brons (Media) Vida Strategic Partners Vida Strategic Partners 415-675-7401 415-675-7402 [email protected] [email protected] Avid Bioservices Reports Financial Results for First Quarter Ended July 31, 2021 and Recent Developments - Recorded First Quarter Revenue of $30.8 Million - - Achieved Fifth Consecutive Quarter of Operational Profitability
August 27, 2021	DEF 14A	First Amendment to 2018 Omnibus Incentive Plan UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin
August 27, 2021	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin
July 14, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 8, 2021 AVID BIOSERVICES, INC.
July 14, 2021	EX-10.1	Form of Notice of Performance Stock Unit Award under 2018 Omnibus Incentive Plan Exhibit 10.1 FORM OF NOTICE OF GRANT OF PERFORMANCE STOCK UNIT AWARD AVID BIOSERVICES, INC. 2018 OMNIBUS INCENTIVE PLAN FOR GOOD AND VALUABLE CONSIDERATION, Avid Bioservices, Inc. (the ?Company?) hereby grants this Performance Stock Unit Award (the ?Award?) of the number of Performance Stock Units set forth in this Notice of Grant of Performance Stock Unit Award (the ?Notice?) to the Grantee desig
July 7, 2021	EX-3.1	Restated Certificate of Incorporation, as filed with the Delaware Secretary of State on July 2, 2021 Exhibit 3.1 RESTATED CERTIFICATE OF INCORPORATION OF AVID BIOSERVICES, INC. Pursuant to Section 245 of the General Corporation Law of the State of Delaware Avid Bioservices, Inc. (the ?Corporation?), a corporation organized and existing under the General Corporation Law of the State of Delaware (the ?DGCL?), hereby certifies as follows: FIRST: The name of the Corporation is Avid Bioservices, Inc.
July 7, 2021	EX-3.2	Certificate of Elimination of Class B Preferred Stock, Class C Preferred Stock, Series D Preferred Stock, and Series E Preferred Stock, as filed with the Delaware Secretary of State on July 1, 2021. Exhibit 3.2 CERTIFICATE OF ELIMINATION OF CLASS B PREFERRED STOCK AND CLASS C PREFERRED STOCK AND SERIES D PREFERRED STOCK AND SERIES E PREFERRED STOCK OF AVID BIOSERVICES, INC. Pursuant to Section 151 (g) of the General Corporation Law of the State of Delaware Avid Bioservices, Inc., a Delaware Corporation (the ?Corporation?), does hereby certify as follows: First: Pursuant to the authority veste
July 7, 2021	8-K	Current Report 8-K 1 avid8k.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 2, 2021 AVID BIOSERVICES, INC. (Exact name of registrant as specified in its charter) Delaware 001-32839 95-3698422 (State of other jurisdiction of
July 1, 2021	EX-99.1	Avid Bioservices Announces Appointment of esther m. alegria, ph.d., to Board of Directors Former SVP of Global Manufacturing at Biogen Has Nearly 30 Years of Biopharmaceutical Industry Experience EX-99.1 2 avidex9901.htm PRESS RELEASE DATED JULY 1, 2021 Exhibit 99.1 Contacts: Stephanie Diaz (Investors) Tim Brons (Media) Vida Strategic Partners Vida Strategic Partners 415-675-7401 415-675-7402 [email protected] [email protected] Avid Bioservices Announces Appointment of esther m. alegria, ph.d., to Board of Directors Former SVP of Global Manufacturing at Biogen Has Nearly 30 Years of Biophar
July 1, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2021 AVID BIOSERVICES, INC. (Exact name of registrant as specified in its charter) Delaware 001-32839 95-3698422 (State of other jurisdiction of incorporation) (Commission Fi
June 29, 2021	EX-4.4	Description of Registrant’s Securities EXHIBIT 4.4 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following summary of the rights of our common stock, $0.001 par value per share (?Common Stock?), and preferred stock, $0.001 par value per share (?Preferred Stock?), does not purport to be complete. This summary is subject to and qualified by the provisions of our ce
June 29, 2021	EX-99.1	Avid Bioservices Reports Financial Results for Fourth Quarter and Fiscal Year Ended April 30, 2021 and Recent Developments -- Recorded Fourth Quarter Revenue of $27.6 Million and Annual Revenue of $95.9 Million -- -- Achieved Four Consecutive Quarter Exhibit 99.1 Contacts: Stephanie Diaz (Investors) Tim Brons (Media) Vida Strategic Partners Vida Strategic Partners 415-675-7401 415-675-7402 [email protected] [email protected] Avid Bioservices Reports Financial Results for Fourth Quarter and Fiscal Year Ended April 30, 2021 and Recent Developments - Recorded Fourth Quarter Revenue of $27.6 Million and Annual Revenue of $95.9 Million - - Achieved
June 29, 2021	EX-4.4	Form of Indenture. EX-4.4 2 avidex0404.htm FORM OF INDENTURE EXHIBIT 4.4 FORM OF INDENTURE AVID BIOSERVICES, INC. Issuer AND as Trustee INDENTURE Dated as of , 20 Debt Securities i CROSS-REFERENCE TABLE(1) SECTION OF TRUST INDENTURE ACT OF 1939, AS AMENDED SECTION(S) OF INDENTURE 310(a) 7.9 310(b) 7.8 311(a) 7.13 311(b) 7.13 312(a) 5.1, 5.2(a) 312(b) 5.2(b) 312(c) 5.2(c) 313(a) 5.4 313(b) 5.4 313(c) 5.4 313(d) 5.4 3
June 29, 2021	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended April 30, 2021 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-32839
June 29, 2021	S-3ASR	As filed with the Securities and Exchange Commission on June 29, 2021 As filed with the Securities and Exchange Commission on June 29, 2021 Registration No.
June 29, 2021	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29, 2021 AVID BIOSERVICES, INC. (Exact name of registrant as specified in its charter) Delaware 001-32839 95-3698422 (State of other jurisdiction of incorporation) (Commission Fi
May 5, 2021	EX-2.1	Agreement and Plan of Merger, dated as of April 30, 2021, by and between Avid SPV, LLC and Avid Bioservices, Inc. Exhibit 2.1 AGREEMENT AND PLAN OF MERGER BETWEEN AVID SPV, LLC AND AVID BIOSERVICES, INC. This AGREEMENT AND PLAN OF MERGER (this ?Agreement?) is made and entered into as of April 30, 2021, by and between Avid SPV, LLC, a Delaware limited liability company (?SPV?), and Avid Bioservices, Inc., a Delaware corporation (?Avid?). RECITALS: WHEREAS, Avid desires to acquire the properties and other asset
May 5, 2021	EX-4.1	First Supplemental Indenture, dated as of April 30, 2021, by and among Avid SPV, LLC, Avid Bioservices, Inc. and U.S. Bank National Association, as trustee Exhibit 4.1 AVID SPV, LLC, as Issuer, AVID BIOSERVICES, INC., as Guarantor AND U.S. BANK NATIONAL ASSOCIATION as Trustee FIRST SUPPLEMENTAL INDENTURE dated as of April 30, 2021 to INDENTURE dated as of March 12, 2021 1.250% EXCHANGEABLE SENIOR NOTES DUE 2026 THIS FIRST SUPPLEMENTAL INDENTURE dated as of April 30, 2021 (this ?Supplemental Indenture?), is among AVID SPV, LLC, a Delaware limited liab
May 5, 2021	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2021 AVID BIOSERVICES, INC. (Exact name of registrant as specified in its charter) Delaware 001-32839 95-3698422 (State of other jurisdiction of incorporation) (Commission F
April 15, 2021	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2021 AVID BIOSERVICES, INC.
April 15, 2021	EX-99.1	AVID BIOSERVICES ANNOUNCES COMPLETION OF REDEMPTION OF SERIES E CONVERTIBLE PREFERRED STOCK Exhibit 99.1 Contacts: Stephanie Diaz (Investors) Tim Brons (Media) Vida Strategic Partners Vida Strategic Partners 415-675-7401 415-675-7402 [email protected] [email protected] AVID BIOSERVICES ANNOUNCES COMPLETION OF REDEMPTION OF SERIES E CONVERTIBLE PREFERRED STOCK TUSTIN, California, April 15, 2021 - Avid Bioservices, Inc. (NASDAQ: CDMO) (the ?company?), a dedicated biologics contract developm
April 12, 2021	EX-99.25	EX-99.25 EX-99.25 2 cdmop-form25.txt cdmop-form25
March 12, 2021	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2021 AVID BIOSERVICES, INC. (Exact name of registrant as specified in its charter) Delaware 001-32839 95-3698422 (State of other jurisdiction of incorporation) (Commission Fi
March 12, 2021	EX-10.1	Form of Capped Call Transactions Confirmation Exhibit 10.1 [] March [], 2021 To: Avid Bioservices, Inc. 2642 Michelle Drive, Suite 200 Tustin, California 92780 Attention: [] Telephone No.: [] Facsimile No.: [] Re: [Base][Additional] Call Option Transaction The purpose of this letter agreement (this ?Confirmation?) is to confirm the terms and conditions of the call option transaction entered into between [] (?Dealer?) and Avid Bioservices, Inc
March 12, 2021	EX-4.1	Indenture, dated as of March 12, 2021, by and among Avid SPV, LLC, Avid Bioservices, Inc. and U.S. Bank National Association, as trustee Exhibit 4.1 AVID SPV, LLC, as Issuer AVID BIOSERVICES, INC., as Guarantor AND U.S. BANK NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of March 12, 2021 1.250% Exchangeable Senior Notes due 2026 TABLE OF CONTENTS Page Article 1 Definitions Section 1.01. Definitions 1 Section 1.02. References to Interest 13 Article 2 Issue, Description, Execution, Registration and Exchange of Notes Section 2.0
March 12, 2021	EX-99.2	Avid Bioservices, Inc. Announces Pricing of $125 Million Offering of Exchangeable Senior Notes Exhibit 99.2 Avid Bioservices, Inc. Announces Pricing of $125 Million Offering of Exchangeable Senior Notes March 10, 2021 TUSTIN, Calif. , March 10, 2021 (GLOBE NEWSWIRE) ?Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP) (the ?company?), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and ma
March 12, 2021	EX-99.1	Avid Bioservices, Inc. Announces Proposed $125 Million Offering of Exchangeable Senior Notes Exhibit 99.1 Avid Bioservices, Inc. Announces Proposed $125 Million Offering of Exchangeable Senior Notes March 8, 2021 TUSTIN, Calif. , March 08, 2021 (GLOBE NEWSWIRE) ? Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP) (the ?company?), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manu
March 8, 2021	EX-99.1	Avid Bioservices Reports Financial Results for Third Quarter Fiscal 2021 and Recent Developments -- Third Quarter Revenue Increased 61% to $21.8 Million -- -- Signed $74 Million in New Orders to End the Quarter with a Backlog of $120 Million -- -- Fi Exhibit 99.1 Contacts: Stephanie Diaz (Investors) Tim Brons (Media) Vida Strategic Partners Vida Strategic Partners 415-675-7401 415-675-7402 [email protected] [email protected] Avid Bioservices Reports Financial Results for Third Quarter Fiscal 2021 and Recent Developments - Third Quarter Revenue Increased 61% to $21.8 Million - - Signed $74 Million in New Orders to End the Quarter with a Backlog
March 8, 2021	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2021 AVID BIOSERVICES, INC.
March 8, 2021	10-Q	Quarterly Report - FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2021 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-32839
March 3, 2021	EX-99.1	AVID BIOSERVICES declares quarterly dividend on its series e convertible preferred stock Exhibit 99.1 Contacts: Stephanie Diaz (Investors) Tim Brons (Media) Vida Strategic Partners Vida Strategic Partners 415-675-7401 415-675-7402 [email protected] [email protected] AVID BIOSERVICES declares quarterly dividend on its series e convertible preferred stock TUSTIN, CA, March 3, 2021 - Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufa
March 3, 2021	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2021 AVID BIOSERVICES, INC.
February 22, 2021	EX-99.1	AVID BIOSERVICES begins phase 2 of its myford Manufacturing capacity expansion plan Build Out of Myford Facility Will Expand Current Footprint to Include Second Manufacturing Train with Both Upstream and Downstream Processing Suites Phase 2 Has Poten Exhibit 99.1 Contacts: Stephanie Diaz (Investors) Tim Brons (Media) Vida Strategic Partners Vida Strategic Partners 415-675-7401 415-675-7402 [email protected] [email protected] AVID BIOSERVICES begins phase 2 of its myford Manufacturing capacity expansion plan Build Out of Myford Facility Will Expand Current Footprint to Include Second Manufacturing Train with Both Upstream and Downstream Processi
February 22, 2021	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2021 AVID BIOSERVICES, INC.
February 16, 2021	SC 13G/A	SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* Avid Bioservices, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) (CUSIP Number) D SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* Avid Bioservices, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 05368M106 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which t
February 12, 2021	SC 13G/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934* (Amendment No. 6) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934* (Amendment No. 6) Avid Bioservices, Inc. (Name of Issuer) Common Stock ($0.001 par value) (Title of Class of Securities) 05368M106 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule purs
January 26, 2021	SC 13G/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 5)* Avid Bioservices, Inc. (Name of Issuer) COMMON STOCK, $0.001 PAR VALUE PER SHARE (Title of Class of Se UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 5)* Avid Bioservices, Inc. (Name of Issuer) COMMON STOCK, $0.001 PAR VALUE PER SHARE (Title of Class of Securities) 05368M106 (CUSIP Number) William Sullivan, 10 Market Street, #773 Camana Bay Grand Cayman, KY1-9006 CAYMAN ISLANDS, 345-640-3330 (Name, Addr
January 19, 2021	SC 13G/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 1) AVID BIOSERVICES, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Secur UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 1) AVID BIOSERVICES, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 05368M106 (CUSIP Number) DECEMBER 31, 2020 (Date of event which requires filing of this statement) Check the appropriate box to designate the r
December 14, 2020	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2020 AVID BIOSERVICES, INC.
December 14, 2020	EX-99.3	AVID BIOSERVICES ANNOUNCES CLOSING OF PUBLIC OFFERING OF COMMON STOCK Exhibit 99.3 Contacts: Stephanie Diaz (Investors) Tim Brons (Media) Vida Strategic Partners Vida Strategic Partners 415-675-7401 415-675-7402 [email protected] [email protected] AVID BIOSERVICES ANNOUNCES CLOSING OF PUBLIC OFFERING OF COMMON STOCK TUSTIN, CA, December 14, 2020 - Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organiz
December 14, 2020	EX-99.1	AVID BIOSERVICES ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK Exhibit 99.1 Contacts: Stephanie Diaz (Investors) Tim Brons (Media) Vida Strategic Partners Vida Strategic Partners 415-675-7401 415-675-7402 [email protected] [email protected] AVID BIOSERVICES ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK TUSTIN, CA, December 9, 2020 - Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organizati
December 14, 2020	EX-99.2	AVID BIOSERVICES ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK Exhibit 99.2 Contacts: Stephanie Diaz (Investors) Tim Brons (Media) Vida Strategic Partners Vida Strategic Partners 415-675-7401 415-675-7402 [email protected] [email protected] AVID BIOSERVICES ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK TUSTIN, CA, December 10, 2020 - Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organiz
December 14, 2020	EX-1.1	Underwriting Agreement, dated December 10, 2020, between Avid Bioservices, Inc. and RBC Capital Markets, LLC. Exhibit 1.1 Avid Bioservices, Inc. 3,333,335 Shares of Common Stock ($0.001 par value) UNDERWRITING AGREEMENT December 10, 2020 RBC Capital Markets, LLC As Representative of the several Underwriters listed in Exhibit A hereto c/o RBC Capital Markets, LLC 200 Vesey Street New York, New York 10281-8098 Ladies and Gentlemen: Avid Bioservices, Inc., a Delaware corporation (the “Company”) confirms its
December 11, 2020	424B5	3,333,335 Shares Common Stock Avid Bioservices, Inc. Common stock 424B5 1 avid424b5.htm PROSPECTUS SUPPLEMENT 424(B)(5) Filed Pursuant to Rule 424(b)(5) Registration No. 333-222548 PROSPECTUS SUPPLEMENT (to Prospectus dated January 25, 2018) 3,333,335 Shares Common Stock Avid Bioservices, Inc. Common stock Avid Bioservices, Inc. is offering 3,333,335 shares of its common stock. Our common stock is listed on The NASDAQ Capital Market under the symbol “CDMO.” The
December 9, 2020	424B5	SUBJECT TO COMPLETION, DATED DECEMBER 9, 2020 Filed Pursuant to Rule 424(b)(5) Registration No. 333-222548 This preliminary prospectus supplement relates to an effective registration statement under the Securities Act of 1933, but the information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell and are not soliciting an
December 7, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 3, 2020 AVID BIOSERVICES, INC.
December 7, 2020	EX-99.1	Avid Bioservices Announces Appointment of jeanne thoma to Board of Directors Exhibit 99.1 Contacts: Stephanie Diaz (Investors) Tim Brons (Media) Vida Strategic Partners Vida Strategic Partners 415-675-7401 415-675-7402 [email protected] [email protected] Avid Bioservices Announces Appointment of jeanne thoma to Board of Directors TUSTIN, CA, December 7, 2020 - Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing o
December 2, 2020	10-Q	Quarterly Report - FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 31, 2020 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-32839
December 2, 2020	8-K	- FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 2, 2020 AVID BIOSERVICES, INC.
December 2, 2020	EX-99.1	Avid Bioservices Reports Financial Results for Second Quarter Fiscal 2021 and Recent Developments -- Recorded Second Quarter Revenue of $21.1 Million -- -- Signed $28 Million in Business Orders and Ended the Quarter with a Backlog of $67 Million -- - Exhibit 99.1 Contacts: Stephanie Diaz (Investors) Tim Brons (Media) Vida Strategic Partners Vida Strategic Partners 415-675-7401 415-675-7402 [email protected] [email protected] Avid Bioservices Reports Financial Results for Second Quarter Fiscal 2021 and Recent Developments - Recorded Second Quarter Revenue of $21.1 Million - - Signed $28 Million in Business Orders and Ended the Quarter with a Bac
December 1, 2020	8-K	Financial Statements and Exhibits, Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 1, 2020 AVID BIOSERVICES, INC.
December 1, 2020	EX-99.1	AVID BIOSERVICES declares quarterly dividend on its series e convertible preferred stock Exhibit 99.1 Contacts: Stephanie Diaz (Investors) Tim Brons (Media) Vida Strategic Partners Vida Strategic Partners 415-675-7401 415-675-7402 [email protected] [email protected] AVID BIOSERVICES declares quarterly dividend on its series e convertible preferred stock TUSTIN, CA, December 1, 2020 - Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and man
October 22, 2020	8-K	Submission of Matters to a Vote of Security Holders - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 20, 2020 AVID BIOSERVICES, INC.
September 15, 2020	EX-99.1	AVID BIOSERVICES ANNOUNCES MOVE TO VIRTUAL-ONLY ANNUAL MEETING OF STOCKHOLDERS ON OCTOBER 20, 2020 Exhibit 99.1 Contacts: Stephanie Diaz (Investors) Tim Brons (Media) Vida Strategic Partners Vida Strategic Partners 415-675-7401 415-675-7402 [email protected] [email protected] AVID BIOSERVICES ANNOUNCES MOVE TO VIRTUAL-ONLY ANNUAL MEETING OF STOCKHOLDERS ON OCTOBER 20, 2020 TUSTIN, CA, September 15, 2020 - Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), today announced that it will hold its
September 15, 2020	EX-3.2	Amended and Restated Bylaws Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF Avid Bioservices, Inc., a Delaware corporation September 11, 2020 TABLE OF CONTENTS Page Article I OFFICES 1 Section 1. Registered Office 1 Section 2. Other Offices 1 Section 3. Books 1 Article II MEETINGS OF STOCKHOLDERS 1 Section 1. Place of Meetings 1 Section 2. Annual Meetings 1 Section 3. Special Meetings 6 Section 4. Notice; Waiver of Notice 6 Secti
September 15, 2020	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 11, 2020 AVID BIOSERVICES, INC.
September 15, 2020	DEFA14A	- DEFINITIVE ADDITIONAL MATERIALS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin
September 1, 2020	EX-99.1	Avid Bioservices Reports Financial Results for First Quarter Ended July 31, 2020 and Recent Developments -- Recorded First Quarter Revenue of $25.4 Million -- -- Signed Three New Customers and Project Expansion Orders with Current Customers for $20 M Exhibit 99.1 Contacts: Stephanie Diaz (Investors) Tim Brons (Media) Vida Strategic Partners Vida Strategic Partners 415-675-7401 415-675-7402 [email protected] [email protected] Avid Bioservices Reports Financial Results for First Quarter Ended July 31, 2020 and Recent Developments - Recorded First Quarter Revenue of $25.4 Million - - Signed Three New Customers and Project Expansion Orders with Cur
September 1, 2020	8-K	- FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 1, 2020 AVID BIOSERVICES, INC.
September 1, 2020	10-Q	Quarterly Report - FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2020 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-32839 AVI
September 1, 2020	EX-10.8	Employment Agreement by and between Avid Bioservices, Inc. and Nicholas S. Green, effective July 30, 2020 Exhibit 10.8 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (“Agreement”) is by and between Avid Bioservices, Inc., a Delaware corporation (“Employer” or the “Company”), and Nicholas S Green (“Executive”). In consideration of the promises and mutual covenants contained herein, and for other good and valuable consideration, receipt of which is hereby acknowledged, the parties hereto do hereby agree
August 31, 2020	EX-99.1	AVID BIOSERVICES declares quarterly dividend on its series e convertible preferred stock Exhibit 99.1 Contacts: Stephanie Diaz (Investors) Tim Brons (Media) Vida Strategic Partners Vida Strategic Partners 415-675-7401 415-675-7402 [email protected] [email protected] AVID BIOSERVICES declares quarterly dividend on its series e convertible preferred stock TUSTIN, CA, August 31, 2020 - Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manu
August 31, 2020	8-K	Financial Statements and Exhibits, Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 31, 2020 AVID BIOSERVICES, INC.
August 27, 2020	DEFA14A	- DEFINITIVE ADDITIONAL MATERIALS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin
August 27, 2020	DEF 14A	Definitive Proxy Statement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ý Defin
July 31, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2020 AVID BIOSERVICES, INC.
July 22, 2020	SC 13G	CDMO / Avid Bioservices, Inc. / INTEGRATED CORE STRATEGIES (US) LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 AVID BIOSERVICES, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 05368M106 (CUSIP Number) JULY 16, 2020 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which
June 30, 2020	EX-4.21	Description of Registrant’s Securities EXHIBIT 4.21 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following summary of the rights of our common stock, $0.001 par value per share (“Common Stock”), and preferred stock, $0.001 par value per share (“Preferred Stock”), does not purport to be complete. This summary is subject to and qualified by the provisions of our c
June 30, 2020	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2020 AVID BIOSERVICES, INC.
June 30, 2020	10-K	Annual Report - FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended April 30, 2020 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-32839
June 30, 2020	EX-99.1	Avid Bioservices Reports Financial Results for Fourth Quarter and Fiscal Year Ended April 30, 2020 and Recent Developments -- Appointed Nicholas Green as President and Chief Executive Officer -- -- Recorded Fourth Quarter Revenue of $12.6 Million and Exhibit 99.1 Contacts: Stephanie Diaz (Investors) Tim Brons (Media) Vida Strategic Partners Vida Strategic Partners 415-675-7401 415-675-7402 [email protected] [email protected] Avid Bioservices Reports Financial Results for Fourth Quarter and Fiscal Year Ended April 30, 2020 and Recent Developments - Appointed Nicholas Green as President and Chief Executive Officer - - Recorded Fourth Quarter Reve
June 25, 2020	EX-99.1	Avid Bioservices Names Nicholas Green as President and Chief Executive Officer Seasoned Executive Brings More than 30 Years of Pharmaceutical and Healthcare Services Industry Experience to Lead Avid Through Next Phase of Growth and Expansion Exhibit 99.1 Contacts: Stephanie Diaz (Investors) Tim Brons (Media) Vida Strategic Partners Vida Strategic Partners 415-675-7401 415-675-7402 [email protected] [email protected] Avid Bioservices Names Nicholas Green as President and Chief Executive Officer Seasoned Executive Brings More than 30 Years of Pharmaceutical and Healthcare Services Industry Experience to Lead Avid Through Next Phase of Gr
June 25, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2020 AVID BIOSERVICES, INC.
June 3, 2020	EX-99.1	AVID BIOSERVICES declares quarterly dividend on its series e convertible preferred stock Exhibit 99.1 Contact: Stephanie Diaz (Investors) Tim Brons (Media) Vida Strategic Partners Vida Strategic Partners 415-675-7401 415-675-7402 [email protected] [email protected] AVID BIOSERVICES declares quarterly dividend on its series e convertible preferred stock TUSTIN, CA, June 3, 2020 - Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufact
June 3, 2020	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2020 AVID BIOSERVICES, INC.
May 15, 2020	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2020 AVID BIOSERVICES, INC.
April 23, 2020	EX-10.1	Promissory Note, dated April 17, 2020, by and between Avid Bioservices, Inc. and City National Bank Exhibit 10.1 U.S. Small Business Administration NOTE SBA Loan # 82686270-00 SBA Loan Name Avid Bioservices, Inc. Date April 17, 2020 Loan Amount Four Million Three Hundred Seventy-Nine Thousand Two Hundred Six Dollars ($4,379,206.00) Interest Rate 1.00% per annum Borrower Avid Bioservices, Inc, a Delaware corporation Operating Company N/A Lender City National Bank 1. PROMISE TO PAY: In return for
April 23, 2020	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 21, 2020 AVID BIOSERVICES, INC.
March 10, 2020	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2020 AVID BIOSERVICES, INC.
March 10, 2020	10-Q	CDMO / Avid Bioservices, Inc. 10-Q - Quarterly Report - FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2020 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-32839
March 10, 2020	EX-99.1	Avid Bioservices Reports Financial Results for Third Quarter Fiscal 2020 and Recent Developments -- Recorded Third Quarter Revenue of $13.6 Million -- -- Signed New Customer and Project Expansion Orders with Current Customers for $20 Million -- -- Ad Exhibit 99.1 Contacts: Stephanie Diaz (Investors) Tim Brons (Media) Vida Strategic Partners Vida Strategic Partners 415-675-7401 415-675-7402 [email protected] [email protected] Avid Bioservices Reports Financial Results for Third Quarter Fiscal 2020 and Recent Developments - Recorded Third Quarter Revenue of $13.6 Million - - Signed New Customer and Project Expansion Orders with Current Customers
March 4, 2020	EX-99.1	AVID BIOSERVICES declares quarterly dividend on its series e convertible preferred stock Exhibit 99.1 Contacts: Stephanie Diaz (Investors) Tim Brons (Media) Vida Strategic Partners Vida Strategic Partners 415-675-7401 415-675-7402 [email protected] [email protected] AVID BIOSERVICES declares quarterly dividend on its series e convertible preferred stock TUSTIN, CA, March 4, 2020 - Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufa
March 4, 2020	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2020 AVID BIOSERVICES, INC.
February 14, 2020	EX-99.1	JOINT FILING AGREEMENT EXHIBIT A JOINT FILING AGREEMENT The undersigned hereby agree that the statement on Schedule 13G with respect to the Common Stock of Avid Bioservices, Inc.
February 14, 2020	SC 13G/A	CDMO / Avid Bioservices, Inc. / Tappan Street Partners LLC - AMENDMENT TO FORM SC 13G Passive Investment grou UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934* (Amendment No. 5) Avid Bioservices, Inc. (Name of Issuer) Common Stock ($0.001 par value) (Title of Class of Securities) 05368M106 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule
February 14, 2020	SC 13G/A	CDMO / Avid Bioservices, Inc. / ISZO CAPITAL LP - AMENDMENT NO. 1 TO THE SCHEDULE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.1)* Avid Bioservices, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 05368M106 (CUSIP Number) December 31, 2019 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which th
February 14, 2020	EX-99.2	EXHIBIT B EXHIBIT B IsZo Capital LP IsZo Capital GP LLC IsZo Capital Management LP Brian L. Sheehy

CDMO / Avid Bioservices, Inc. - Pemfailan SEC, Laporan Tahunan, Penyata Proksi

Statistik Asas

SEC Filings

SEC Filings (Chronological Order)